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Abstract 
Rheumatoid arthritis is a chronic autoimmune disease characterized by progressive articular 
damage, functional loss and comorbidity. The advent of effective biologic and small molecule kinase 
inhibitors in recent years has substantially improved clinical outcomes.   Just as pathogenesis 
understanding lead in large part to the advent of such therapeutics, so mode of action studies of 
these specific immune targeted agents have shed new light on the immune pathways that drive 
articular inflammation and related co-morbidities.  Thus cytokine inhibitors have definitely proven a 
hierarchically important position for TNF and IL-6 in disease pathogenesis with a likely role also for 
GM-CSF, but not IL-1, or IL-17.  More recently, Janus kinase inhibitors have demonstrated that 
cytokine receptor families served by JAK/STAT dependent signaling are critical for disease, in part 
replicating the findings for IL-6 blockade but adding new knowledge as to the roles played by other 
cytokines e.g. the interferons.  Finally, co-stimulatory blockade and B cell depletion demonstrate 
that the adaptive immune response, and other downstream pathways initiated by these cells, likely 
participate directly in synovial inflammation.  Taken together, understanding the actions of specific 
immune interventions can elucidate definitive molecular or cellular nodes that are essential to 
maintain complex inflammatory networks that sub-serve disease. 
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Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterized by articular destruction 
associated increasingly over time with co-morbidities in vascular, metabolic, bone and psychological 
domains.  RA affects up to 1% of the population, more often females and can present across the age 
decades.  The primary aetiopathogenesis of RA is considered to be autoimmune, comprising a pre-
RA phase in which systemic immune mediators e.g. autoantibodies and cytokines, are detected, 
leading thereafter to clinically evident, articular onset of ‘early RA’ that evolves into chronic 
inflammation (‘established RA’) associated with tissue remodeling and damage.  Recent advances in 
the development of specific immune targeted therapeutics including biologics and kinase inhibitors 
have revolutionized clinical care and remarkably improved outcomes.  Equally they have provided 
definitive proof of concept in unravelling the pivotal molecular and cellular nodes that reside within 
the complex inflammatory networks that propagate and perpetuate disease. In this short review we 
will summarize the key pathogenetic lessons learned and implications derived from the bio-
therapeutic revolution of the last two decades in RA. 
 
Considerations around RA pathogenesis 
The pathogenesis of RA has been extensively reviewed recently and will be summarized only briefly 
herein [1-3].  The genetics of RA have been explored by conventional and genome wide approaches 
and the genetic architecture of the disease is well defined.  Over 100 loci are associated with disease 
risk and progression and the majority implicate immune effector or regulatory gene products [4].  
Prominent amongst these are the MHC class II locus, especially HLA DR01/04 implicating T cells 
recognizing autoreactive peptide, co-stimulatory pathways, including CD28, CD40, chemokines and 
cytokine receptors (e.g. IL-6R), post translational modification enzymes e.g. PADI and intracellular 
regulatory pathways e.g. PTPN22, TNFAIP3, STAT3 all of which may alter the threshold for immune 
activation or failed regulation.  It is recognized however that powerful epidemiologic effects operate 
upon this genetic background to promote disease.  Extensive evidence supports a role for smoking 
(especially in HLADR01/04+ individuals), and other pulmonary exposures including silica dust, 
together with additional variables e.g. vitamin D deficiency, obesity as pro-disease inducing factors 
[1,5].  In addition, there is evidence of a perturbed microbiome in the GI tract whereby long-term 
impacts on immune regulation and maintenance of host tolerance could be enacted, and also in the 
oral mucosa where P. gingivalis, or A. actinomycetemcomitans, have been proposed to promote 
disease via altered tissue citrullination [6,7].  Overall the earliest events in ‘pre-RA’ comprise altered 
innate immune reactivity and aberrant T cell / B cell cross regulation, likely in mucosal tissues, 
culminating in the emergence of autoantibodies that recognise a range of post translationally 
modified proteins that include those containing citrulline residues (anti-citrullinated autoantibodies - 
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ACPAs); though recent studies have also identified anti-carbamylated and anti-acetylated 
specificities.    
 
How such autoreactivity transforms the normally acellular synovium into a chronically inflamed 
tissue is poorly understood.  Articular localisation may arise from local microtrauma, microvascular 
insult, local complement activation, or may reflect direct activation of periarticular osteoclasts by 
circulating ACPAs that initiate bone damage and local IL-8 release to initiative synovitis [8,9].  The 
synovial lesion once established contains large numbers of infiltrating T cells, B cells, plasma cells, 
mast cells and macrophages, contained within a disrupted extracellular matrix and activated, 
stromal cells, especially synovial fibroblasts.  Understanding the complex interplay of cells and 
soluble immune mediators particularly cytokine and chemokine families has been challenging, 
particularly when the dimension of disease duration is included.  Animal models have been of some 
assistance but have not always faithfully reflect the human condition.   As such it is timely to 
consider the invaluable opportunity offered by investigating the success and failure of specific 
targeted immune therapeutics in RA – in this sense they are serving as molecular scalpels to dissect 
mechanisms of disease. 
 
TNF and IL-6 as critical disease effector pathways 
Given their longevity in the field, the majority of studies have investigated the biology of TNFi in RA.  
Early studies identified rapid diminution of circulating IL-6 upon TNF blockade in RA consistent with 
existence of a functional cytokine hierarchy in vivo that in turn regulated the acute phase response 
[10].  Thereafter, a series of elegant studies using either arthroscopic or ultrasound guided synovial 
biopsies obtained prior to and after TNFi administration in patients demonstrated profound 
alterations including reduced cellular number and phenotypic composition, stromal cell activation, 
angiogenesis (including endothelial activation, neovascularization and adhesion molecule 
expression), increased lymphangiogenesis, altered cytokine and chemokine expression to favour 
regulatory pathways e.g. IL-10, altered matrix metalloporoteinase / tissue inhibitor of MMP ratios 
and tissue macro-architecture [11-18].  Cellular imaging studies in vivo after TNFi similarly provided 
estimations for the first time of the tissue kinetics of monocytes in RA and demonstrated a pivotal 
role for TNF therein. Systemic studies investigating biomarkers have elucidated remarkable effects 
on bone turnover and metabolism, and also to some extent on lipid and glucose metabolism. These 
effects have now been examined at the transcriptional and metabolomics level in which rather 
exquisite effects are mediated, even within the TNFi class by distinct agents suggesting that more 
detailed mechanistic understanding may yet be possible in future studies with advanced molecular 
McInnes IB & Schett G March 2017  
 5 
and informatics approaches [19.20].   Nevertheless, this clinical evidence base, when combined with 
relevant ex vivo and in vitro studies that have liberally explored the biology of TNF in relevant tissue 
and cellular systems, clearly places TNF at the centre of RA pathogenesis.  Moreover, they define the 
pleiotropic functional effects that TNF plays in this complex pathogenetic landscape.  
  
Similar lessons are emerging from studies of IL-6Ri, primarily using tocilizumab.  A majority of studies 
have examined the effects of IL-6Ri in circulating cell populations. Many have focused on the 
transcriptional changes that are mediated upon IL-6Ri.    Primarily performed to seek biomarkers for 
response prediction, these nevertheless offer an insight into the pathways that are dependent upon 
IL-6 signaling in the disease and have so far correlated with interferon signal pathways in peripheral 
blood [21].  Synovial studies are more limited but demonstrate that IL-6R blockade leads to 
reduction in T cell activation markers and chemokine expression but also induced pro-repair gene 
sets [22].  These changes are discrete when compared with those noted upon B cell depletion and 
TNF inhibition suggesting some degree opf specificity in synovial changes upon IL-6R blockade. That 
synovial IL-6 levels can also predict subsequent responses to IL-6R blockade has also been suggested 
suggesting that the absolute local IL-6 concentration is of pathologic importance [23].   Taken 
together these studies suggest that IL-6 occupies a pivotal position in regulating both T cell 
migration, and activation but also in the downstream inflammatory response.  IL-6 also p[lays a 
pivotal roel in comorbidity discussed below. Granulocyte-macrophage colony-stimulating factor 
(GM–CSF) is a pro-inflammatory soluble cytokine implicated by several previous studies in the 
pathogenesis of RA [24]. Via binding to GM–CSF receptor alpha (GM–CSFRα), GM-CSF activates 
neutropihls and macrophages in models of arthritis and macrophages and neutrophils in rheumatoid 
inflammatory tiossues ex vivo; recent clinical trials have been successful providing human proof of 
concept for a pivotal role [25].   Functional studies in synovial tissues are awaited.  
 
The recent advent of inhibitors of Janus kinases (JAK) has brought substantial new opportunity to 
investigate the activities of a broad range of cytokines in RA pathology.   JAKs subserve the signal 
pathways of many cytokine receptors and as such allow examination of the inhibition simultaneously 
of a number of cytokines including IL-6, GM-CSF, type I interferons and the common g-chain 
cytokines such as IL-7 and IL-15.   Thus far tofacitinib, an inhibitor of JAK1/3, and very recently 
baricintib, an inhibitor of JAK1/2 have received regulatory approval.  Most mechanistic insights have 
been gained in evaluating tofacitnib bioeffects. A variety of ex vivo studies using cells purified from 
RA patients indicate that broad suppressive effects are mediatied upon synovial T cells, B cells and 
fibroblast like synoviocytes by tofacitinib operating directly and via inhibition of local cytokine 
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dependent feedback loops [26-28]. Few studies have yet examined synovial responses.  One elegant 
study demonstrated that after 4 weeks of tofacintib treatment there were reductions in MMP 
expression and several chemokines including CCL2, CXCL10 and CXCL13 [29].  Tissue inflammation 
scores including T cell B cell and macrophage numbers were not altered perhaps reflecting a 
relatively early time point. STAT1 and STAT3 phosphortylation was also diminished consistent with 
the propsode mode of action of tofacinitib in synovitis. Future bipsy studies will be important to 
dissect the impact of varied JAK pathway selectivity across this emerging drug class. 
 
It is worth considering the range of cytokine inhibitors that have been trialed unsuccessfully in RA.   
For example, IL-1 blockade achieves at best modest improvement as does IL-17A blockade, at least 
used as mono-biologic therapy [30].   Other studies demonstrated no benefit from IL-23 inhibition 
despite propitious pre-clinical data [31].   Thus the notion that RA is a ‘Th17’ disease, as 
demonstrated clearly for psoriasis and axial spondyloarthropathies is not sustained by the clinical 
evidence base.   It is important to note however that this does not infer that such cytokines are not 
functionally active in RA synovium – they most likely are – but simply implies that these cytokines do 
not occupy a sufficiently vital role in the hierarchy of inflammation to lead to disease diminution 
upon their inhibition, or that they are targeted at a time point when their functional contribution is 
no longer pivotal  [32].  
 
 T cells in RA 
The biologic role of T cells in RA pathogenesis has long been debated.  The strong genetic clues from 
MHC Class II and costimulatory pathway associations, critical role min animal models, and plausible 
place in driving host autoreactivity, including the identification of oligo clonal T cells in synovial 
biopsies are all suggestive of a beneficial role for T cell modulators [2].  However clinical trials in 
which T cells were depleted or functionally modified using ciclosporin, anti-CD4, anti-CD5 or 
Campath-1H did not yield robust clinical responses.  In contrast the advent of abatacept as a 
costimulator inhibitor targeting the CD28 – CD80/86 pathway finally delivered a T cell targeted 
therapeutic of value. Robust clinical responses analogous to those achieved with TNFi are observed.  
Abatacept is a potent modulator of T cell activation in ex vivo studies though importantly it does not 
appear to enhance regulatory T cell responses.  Abatacept also favorably reduces intercations 
between T cells, dendritic cells and macrophages to reduce down stream cytokine release [33, 34] 
and may inhibit osteoclastogenesis [33,34]. Murine models show that at least some of the beneficial 
effects of abatacept are mediated via reduction of reverse licencing of dendritic cells by T cells 
though such data are currently being investigated in human trials [35].  Synovial biopsy studies have 
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shown that abatacept leads to reduced cellular infiltration though this was most marked for B cells 
indicative of active cross talk between synovial T cells and B cells. Generalised reduction in 
inflammatory cytokine expression was also noted in one study; the consensus is that such changes 
may operate downstream from T cell costimulatrory blockade [36,37].   These studies have 
refreshed interest in targeting T cell dependent effector and regulatory pathways for the future 
development of therapeutics.  
 
B cells in pathogenesis of RA  
The role of B cells in RA is highlighted by the autoantibody response comprising high affinity IgG 
antibodies against citrullinated, carbamylated and acetylated proteins. Generation of such 
antibodies requires T cell help and affinity maturation of B cells in lymphoid follicles leading to the 
formation of plasmablasts and autoantibody production. Apart from autoantibodies, biopsy studies 
have shown that B cells and plasma cells are abundantly present in the synovial membrane of RA 
patients and sometimes form aggregates or even tertiary lymphoid follicles suggesting local 
production of autoantibodies in the joints. Despite this robust evidence for the involvement of B cell 
mediated immune processes in RA, the profound anti-inflammatory potential of the B cell depleting 
treatment in RA was only partially expected, and reemphasised the role of adaptive immunity in RA 
at a time when T cell depletion had effectively failed [38, 39] 
 
Treatment with rituximab, an antibody binding to the B cell specific surface molecule CD20 leads to 
sustained virtually complete depletion of peripheral B cells, while B cells at sites of inflammation 
such as the synovium are only partially affected [40]. Plasma cells, especially long-lived plasma cells, 
which lack CD20 expression, are not directly affected by rituximab treatment. Most clinical evidence 
suggests that rituximab in contrast to cytokine blocking agents works best in autoantibody–positive 
RA suggesting that rituximab indeed targets the adaptive immune dysfunction in RA [41]. Rituximab 
lowers autoantibody titres but this does not explain anti-inflammatory activity, which develops 
before the decrease in autoantibody titres is observed. Such effects are not fully understood but 
likely arise from rapid depletion of circulating B cells and a proportion of tissue B cells and 
plasmablasts.  B cells are cytokine-producing cells and also have antigen-presenting properties, 
which are likely blunted in a fast and sustained manner by rituximab. On the other hand, the slow 
decrease in autoantibody titres in RA patients upon rituximab treatment suggests that these 
antibodies do not necessarily stem from long-lived plasma cells, but rather result from continuous B 
cells activation and plasmablast differentiation [42,43]. Extensive synovial biopsy studies have 
demonstrated depletion of tissue CD20+ B cells and plasmablasts, variable effects on 
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immunoglobulin synthesis, subsequent reductions in CD68+ macrophages and T cells, limited effects 
on lymphocytic aggregates and enhanced repair gene profiles [44-51].   Sustained low disease 
activity is associated with reduced B cell repopulation, that in turn has been associated with CXCL13 
and CCL19 expression [52,53].  Intriguing pre-therapeutic gene signatures have been defined that 
predict rituximab responsiveness suggesting that there is a B cell defined effector pathway with 
hierarchical pre-eminence [54].  
 
Based on these encouraging pathologic insights, other CD20-targeted antibodies (e.g. 
obinutuzumab, ibrtumomab, ocaratuzumab) that could offer more potent depletion properties were 
considered but have either not started or advanced to larger scale trials in RA with the exception of 
the anti-CD20 antibody ocrelizumab which showed clinical efficacy in RA but was stopped due to 
increased infectious risk [55]. In contrast to complete B cell depletion a more subtle approach 
concerns inhibition of B cell modulatory cytokines. Atacicept, a fusion protein targeting two 
molecules required for B cell maturation and survival, BAFF und APRIL was studied in RA but failed to 
show significant anti-inflammatory activity despite lowering rheumatoid factor and circulating B cells 
levels [56]. Other interesting to target B cells in RA include development and focus on essential 
signalling molecules such as Brutons tyrosine kinase (Btk) and spleen tyrosine kinase (Syk). Syk is a 
critical signalling component downstream of the B cell- and Fc receptor and therefore important for 
a variety of cells involved in the pathogenesis of RA such as B cells, macrophages and osteoclasts. 
One Syk inhibitor (fostamatinib) advanced to phase 3 trials in RA, however efficacy was discouraging 
[57]. Btk is a kinase downstream of the B cell receptor and essential for B cell development and 
function and hence an interesting target in autoimmune diseases. Genetic absence of Btk in humans 
is associated with impaired B cell development and agammaglobulinemia. Small molecule inhibitors 
of Btk are available and currently used for the treatment of mantle cell lymphoma, while others are 
in early development for RA [58].   The variable responses thus far detected to kinase inhibitors 
however reflects our relatively limited understanding of the true cellular hierarchy of these 
pathways at the synovial pathogenetic level.  
 
Taken together with the abatacept datasets alluded before, current evidence defines adaptive 
immune pathways as a non-redundant contributor in the RA inflammatory cascade. However, it 
remains possible that most clinically relevant effector pathways ultimately operate via ‘downstream’ 
TNF and IL-6 [59]. 
 
Targeting resident cells in the joint 
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RA is characterized by a profound resident tissue response associated with the formation of a 
hyperplastic synovial membrane, which acts as a cytokine producing tissue, facilitates the 
development of structural damage and most likely mediates the chronicity of the disease with high 
relapse rates when stopping treatment [60]. This process is based on a sustained activation of 
synovial fibroblasts, which proliferate and develop resistance to apoptosis. Epigenetic modifications 
of these cells by the inflammatory environment may allow sustained activation of the cells allowing 
the chronicity of disease and its substantial risk for recurrence when treatment is stopped [61].  
Targeting of synovial fibroblasts in RA is in its infancy but may open new possibilities for long-term 
remission of disease and so far unprecedented possibilities to modify the diseases by rebooting the 
inflammatory microenvironment in the joint. Several approaches can be envisioned: (i) Formation of 
the hyperplastic synovial lining layer in RA requires homotypic cell assembly requiring the cadherin-
11 adhesion molecule [62]. Blockade of cadherin-11 by neutralizing antibodies may effectively block 
or disrupt such hyperplastic synovial lining layer. Other approaches the can be envisioned is 
targeting molecules which are responsible for the proliferation of synovial fibroblasts such as 
synoviolin or Tyro-3 [63, 64]. Finally, targeting the epigenetic modifications of synovial fibroblasts in 
RA such as histone acetylation or bromodomain and extra-terminal (BET) proteins are interesting 
approaches, which may reverse the proinflammatory microenvironment, which continuously 
attracts immune cells to the joint [65-67]. Such approaches targeting resident cells in the joint are 
not necessarily anti-inflammatory requiring the modification of the design of respective trials in RA.  
Such data will also definitively place the stromal cell within the functional immune hierarchy of RA 
pathogenesis.  
 
A potential future role for cellular therapy to treat inflammation in RA? 
Modification of the inflammatory process by immune modulatory cells or cells inducing tolerance 
have always been an attractive vision to treat autoimmune diseases but have so far not progressed 
to clinical application in RA. This lag in the development of cellular therapies inducing tolerance has 
several reasons, which are based on challenges related to (i) absence of a single autoantigen 
triggering immunity in RA, (ii) challenges in feasibility and standardization of cell-based therapy 
approaches targeting joint disease and (iii) the success of biologic and small-molecule drug 
approaches to treat RA.  Nonetheless cell-based therapeutic approaches could represent an 
attractive additional possibility to achieve long-term tolerance or suppression of inflammation in RA. 
Potential future approaches comprise the transfer of tolerogenic dendritic cells, immune regulatory 
mesenchymal stem cells or regulatory T cells. The principal feasibility of transfer of in vitro 
generated tolerogenic dendritic cells exposed to autologous antigens locally into the joints of RA 
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patients has been shown recently [68,69]. Furthermore, a small trial showed that administration of 
allogeneic adipose-derived mesenchymal stem cells has an effect on treatment-resistant RA [70].  
 
Mechanisms of structural damage  
RA leads to progressive damage as a result of continuous direct exposure of bone and cartilage to 
the inflammatory microenvironment. Bone loss starts very early in the disease course of RA [71]. It is 
driven by the induction of bone-resorbing osteoclasts by autoantibodies, leading to the first 
structural changes in the pre-disease phase and aggravated by the action of proinflammatory 
cytokines [72,73]. Presence of autoantibodies and duration of arthritis, resembling the exposure 
time of bone to inflammatory cytokines,  therefore resemble the key factors determining bone and 
cartilage damage in RA. Therapeutic strategies to timely and effectively block the inflammatory 
synovial process have therefore proven effective to successfully retard structural bone and cartilage 
damage in RA [2].   Osteoclasts as the main bone resorbing cells are highly responsive to antibodies 
and inflammatory cytokines in particular TNF, IL-1 and IL-6/IL-6R complexes, which all induce 
osteoclast differentiation either directly or by inducing the master differentiation factors of 
osteoclasts, RANKL [74]. Therefore, treatment with cytokine inhibitors is particularly effective in 
preventing structural damage even in the absence of full control of inflammation. In support of this 
concept, the blockade of the downstream effector cytokine RANKL with denosumab inhibited the 
progression of bone erosions in patients with RA [75]. Direct down regulation of osteoclast function 
is also achieved by other modes of treatment such as the co-stimulation inhibitor abatacept, which 
binds osteoclasts via CD80 and CD86 and inhibits their differentiation [76]. Furthermore, JAKi may 
indirectly affect osteoclast function through blocking the action of IL-6/IL-6R signalling in osteoclasts 
and hence preserve bone form resorptive damage. Together these clinical trials have unequivocally 
implicated cytokine networks in pathogenetic bone damage in RA.  
 
Mechanisms of major comorbidities  
RA is associated with up to 2-fold increased risk of myocardial infarction and stroke independent 
from classical risk factors for atherogenesis [77]. The intrinsic elevation of cardiovascular risk in RA 
may be considered to result from systemic immune activation and inflammation. Chronically 
elevated serum levels of acute phase reactants such as C-reactive protein as well as 
proinflammatory cytokines, such as TNF and IL-6, are associated with enhanced atherogenesis and 
the development of cardiovascular events per se [78]. The duration and severity of inflammatory 
disease activity have been identified as factors leading to increased cardiovascular risk in RA. 
Furthermore, other factors such disease-associated functional disability and glucocorticoid intake 
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further increase the development of cardiovascular risk [79].  Several clinical studies have elucidated 
underlying mechanisms in the clinical context. Distinct changes in the lipid profile have been 
described in RA and other forms of chronic inflammation such as sepsis [80]; RA is associated with 
decreased levels in total cholesterol, high-density lipoprotein cholesterol (HDL-C) and low-density 
lipoprotein cholesterol (LDL-C). Furthermore, lipoprotein particles such as HDL change their 
composition with higher contents of acute phase proteins such as serum amyloid A (SAA) in RA 
patients. Particularly pronounced effects on the altered lipid metabolism in RA are found with the IL-
6R blockade either by tocilizumab or downstream signaling blockade by JAK inhibition. Hence, 
decreased total cholesterol, high-density (HDL-C) and low-density lipoprotein cholesterol (LDL-C) 
levels and the disease-related changes of lipid particle composition revert upon IL-6R pathway 
inhibition [81]. Most importantly control of inflammation in RA has shown to affect cardiovascular 
risk: Methotrexate moderately lowers cardiovascular risk in RA [82]. Larger epidemiologic registers 
have also revealed a protective effect of TNF inhibitors on cardiovascular events in RA [83,84].  The 
MEASURE study definitively linked IL-6R signalling to these lipid particle assembly changes in RA [85].   
Aside from cardiovascular disease RA is also complicated by central nervous system changes which 
are reflected in enhanced depression and central sensitization to pain.  These effects are considered 
to result from the action of proinflammatory cytokines, particularly TNF and IL-6 on the central 
nervous system. In accordance, TNF inhibition rapidly reduces pain sensitization in the brain and also 
normalizes the dysbalance of the serotonin homeostasis in the brain of RA patients [86-88]. Similar 
effects are also emerging for IL-6R inhibition.  
 
Prevention of disease and tolerance induction based on the foregoing?  
Current treatment of RA aims for rapid and sustained suppression of inflammation once the 
inflammatory phase of the disease has started and patients present with joint swelling. Achieving 
immunological reset in RA patients is an ambitious future goal on the way to cure the disease, 
though such approaches are in their infancy.  The observation that autoimmunity forms years before 
the inflammatory phase of the disease (often referred to as “pre-RA”), however, opens a therapeutic 
window for disease prevention [89-91]. Several approaches can be envisioned to induce 
immunological “reset” and gain immune tolerance: (i) Targeting T-/B-cell responses required for 
autoantibody production by drugs such as rituximab and abatacept could be used in the pre-RA 
phase with the aim to achieve seroconversion and prevention of disease onset. In this context, the 
Prevention of RA by Rituximab (PRAIRI) studym which aims to retard or even prevent the onset of RA 
by a single-shot rituximab treatment is the most advanced study [92]. In addition, at least two trials 
with abatacept are underway addressing this concept. (ii) In addition, new concepts to modify the 
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pathogenic potential of antibodies with respect to their proinflammatory cytokine-inducing 
properties are being developed.  (iii) Reduction of antigen expression and prevention of the 
formation of pathogenic immune complexes in RA is another promising approach to induce 
tolerance [93]. Cessation of smoking, which is the main environmental factor inducing the 
citrullination of proteins, is most likely the easiest and most cost-effective approach in this respect 
but other targeted approaches such as small-molecule inhibitors of peptidyl deiminases, the 
enzymes responsible for protein citrullination, are in development [94]. (iv) Induction of antigen-
specific tolerance by cell-based treatment approach such as the tolerogenic dendritic cells loaded 
with autoantigens as described above or by the use of tolerogenic nanoparticles loaded with 
peptides involved in the autoimmune response of RA [95,96]. All such approaches do not primarily 
aim to target inflammation but rather the underlying immune dysregulation in RA. Hence, such 
approaches may to be particularly useful in the preclinical phases of RA to prevent disease onset or 
in stable-remission phases of disease to prevent relapses after cessation of anti-inflammatory 
treatment.  
 
In summary the revolution in immune and signal pathway targeted therapeutics have provided 
defintive immunologic check points or vulnerable nodes that place adaptive and downstream 
cytokine effector pathways at the centre of disease pathogenesis (Figure 1).  The future challenge is 
to bulid on such observations to achieve the ultimate ambition namely achievement of immunologic 
homeostasis and drug free remission.  
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